Multicenter, Single Arm, Open-Label Phase II Trial On The Efficacy Of Ortataxel In Recurrent Glioblastoma
Phase of Trial: Phase II
Latest Information Update: 28 Jan 2017
At a glance
- Drugs Ortataxel (Primary) ; Fotemustine
- Indications Glioblastoma
- Focus Therapeutic Use
- 09 Feb 2016 Planned primary completion date changed from 1 Mar 2015 to 1 Dec 2015 as per ClinicalTrials.gov record.
- 09 Feb 2016 Status changed from recruiting to suspended as per ClinicalTrials.gov record.
- 06 Dec 2013 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.